임상시험 시장 : 단계별, 시험 설계별, 서비스 유형별, 치료 분야별 - 세계 예측(2024-2032년)

Global Clinical Trials Market will witness 5.4% CAGR between 2024 and 2032 fueled by an increase in case studies from leading research companies. These studies provide valuable insights into the efficacy and safety of new treatments, driving the need for extensive and diverse clinical trials. Research companies are investing in advanced methodologies and technologies to conduct these trials, addressing various medical conditions and patient populations. For instance, in August 2024, NeuroSense Therapeutics Ltd., a biotechnology firm in late-stage clinical development focused on novel treatments for severe neurodegenerative diseases, announced positive 12-month iron biomarker results from its Phase IIb study (PARADIGM).

As case studies demonstrate the benefits of novel therapies and innovative treatment approaches, there is a heightened focus on conducting rigorous clinical trials to validate these findings. This trend is further supported by the rising prevalence of chronic diseases and the ongoing quest for personalized medicine. The continuous flow of case studies not only supports the development of new treatments but also enhances regulatory approvals and market entry, propelling demand within the clinical trials sector and advancing the overall healthcare landscape.

The overall Clinical Trials Industry is classified based on the phase, study design, service type, therapeutic area, and region.

Based on phase, the clinical trials market revenue from the phase III segment will register a commendable CAGR from 2024 to 2032. Phase III trials involve large patient populations and are designed to confirm the results of earlier phases, providing comprehensive data on a drug's efficacy and potential side effects. This stage is crucial for gaining market approval and ensuring that treatments meet stringent regulatory standards. The increasing prevalence of chronic diseases and the need for innovative therapies drive demand for Phase III trials, making them a focal point in the drug development process.

In terms of study design, the observational study segment will witness an appreciable growth from 2024 to 2032. Unlike interventional trials, observational studies collect data without influencing treatment decisions, providing insights into how therapies perform in everyday clinical settings. These studies are valuable for assessing long-term effects, patient adherence, and comparative effectiveness of treatments. The increasing focus on personalized medicine and evidence-based practice drives the demand for observational research. Additionally, regulatory agencies and healthcare providers use these studies to inform guidelines and improve patient care, further boosting the need for comprehensive observational data.

Europe clinical trials market will exhibit a notable CAGR from 2024 to 2032. European countries offer a diverse patient population and regulatory environment conducive to clinical trials, making them attractive for global studies. The rising prevalence of chronic diseases and the push for innovative therapies drive the demand for clinical trials. Additionally, Europe's emphasis on high standards for clinical research and patient safety enhances the attractiveness of the region for conducting trials. The combination of these factors, along with supportive regulatory frameworks, fuels significant growth in the European clinical trials sector.

Table of Contents

Chapter 1 Methodology & Scope

• 1.1 Market scope & definitions
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates & calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360° synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Increasing prevalence of chronic diseases across the globe
    • 3.2.1.2 Growing demand for outsourcing clinical trials to CROs
    • 3.2.1.3 Rise in government and non-government funding for clinical trials
    • 3.2.1.4 Growing opportunities for conducting clinical trials in countries of Asia Pacific
  • 3.2.2 Industry pitfalls & challenges
    • 3.2.2.1 Lack of skilled workforce in clinical research
    • 3.2.2.2 Infrastructural barriers in developing countries
    • 3.2.2.3 Challenges faced in North America & Europe for conducting clinical trials
• 3.3 Growth potential analysis
• 3.4 Clinical trials volume analysis
  • 3.4.1 Clinical trials volume analysis, by region, 2021-2023
  • 3.4.2 Clinical trials volume analysis, by phase of development, 2021-2023
  • 3.4.3 Clinical trials volume analysis, by indication, 2021-2023
• 3.5 Regulatory landscape
  • 3.5.1 U.S.
  • 3.5.2 Europe
  • 3.5.3 Asia Pacific
    • 3.5.3.1 Singapore
    • 3.5.3.2 Malaysia
    • 3.5.3.3 Indonesia
    • 3.5.3.4 Thailand
    • 3.5.3.5 South Korea
    • 3.5.3.6 Philippines
• 3.6 Clinical trails - Asia Pacific advantage
• 3.7 Porter's analysis
• 3.8 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

• 4.1 Introduction
• 4.2 Company matrix analysis
• 4.3 Merger & acquisition landscape
• 4.4 Competitive analysis of major market players
• 4.5 Competitive positioning matrix
• 4.6 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Phase, 2021 - 2032 ($ Mn)

• 5.1 Key trends
• 5.2 Phase I
• 5.3 Phase II
• 5.4 Phase III
• 5.5 Phase IV

Chapter 6 Market Estimates and Forecast, By Study Design, 2021 - 2032 ($ Mn)

• 6.1 Key trends
• 6.2 Interventional study
• 6.3 Observational study
• 6.4 Expanded access study

Chapter 7 Market Estimates and Forecast, By Service Type, 2021 - 2032 ($ Mn)

• 7.1 Key trends
• 7.2 Outsourcing service
• 7.3 In-house service

Chapter 8 Market Estimates and Forecast, By Therapeutic Area, 2021 - 2032 ($ Mn)

• 8.1 Key trends
• 8.2 Autoimmune disease
• 8.3 Oncology
• 8.4 Cardiology
• 8.5 Infectious disease
• 8.6 Dermatology
• 8.7 Ophthalmology
• 8.8 Neurology
• 8.9 Hematology
• 8.10 Other therapeutic areas

Chapter 9 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

• 9.1 Key trends
• 9.2 North America
  • 9.2.1 U.S.
  • 9.2.2 Canada
• 9.3 Europe
  • 9.3.1 Germany
  • 9.3.2 UK
  • 9.3.3 France
  • 9.3.4 Spain
  • 9.3.5 Italy
  • 9.3.6 Poland
  • 9.3.7 Netherlands
  • 9.3.8 Switzerland
  • 9.3.9 Rest of Europe
• 9.4 Asia Pacific
  • 9.4.1 China
  • 9.4.2 Japan
  • 9.4.3 India
  • 9.4.4 Australia
  • 9.4.5 South Korea
  • 9.4.6 Singapore
  • 9.4.7 Malaysia
  • 9.4.8 Indonesia
  • 9.4.9 Thailand
  • 9.4.10 Philippines
  • 9.4.11 Rest of Asia Pacific
• 9.5 Latin America
  • 9.5.1 Brazil
  • 9.5.2 Mexico
  • 9.5.3 Argentina
  • 9.5.4 Rest of Latin America
• 9.6 Middle East and Africa
  • 9.6.1 Saudi Arabia
  • 9.6.2 South Africa
  • 9.6.3 UAE
  • 9.6.4 Rest of Middle East and Africa

Chapter 10 Company Profiles

• 10.1 Charles River Laboratories (MPI Research)
• 10.2 Clinipace Inc.
• 10.3 Eli Lilly and Company
• 10.4 ICON plc
• 10.5 IQVIA Inc
• 10.6 Laboratory Corporation of America Holdings (Covance Inc)
• 10.7 Medpace, Inc.
• 10.8 Merck & Co
• 10.9 Parexel International Corporation
• 10.10 Pfizer Inc.
• 10.11 SGS SA
• 10.12 Syneos Health
• 10.13 The Emmes Company, LLC
• 10.14 Thermo Fisher Scientific (PPD Inc)
• 10.15 Veeda Clinical Research
• 10.16 Worldwide Clinical Trials
• 10.17 WuXi AppTech